VALNEVA : GE Healthcare and Valneva Collaboration Delivers Optimized Cell Culture Medium for Vaccine Production
02 Novembre 2016 - 7:10AM
- Collaboration jointly developed a new medium optimized for
productivity of virus expression in EB66® cells
- Robust production process will increase reliability and
end-product quality
GE Healthcare's Life Sciences business and Valneva SE, a fully
integrated vaccine biotech company, are sharing the results of a
successful collaboration to optimize virus productivity in
Valneva's EB66® cell-line, a proprietary technology for the
production of a wide variety of vaccines, including human and
animal health vaccines. Viral production in EB66® cells encompasses
secreted viruses, such as measles, alphaviruses, influenza A and B
strains, and intracellular viruses, such as the modified vaccinia
Ankara (MVA) virus.
The collaboration has resulted in the creation of a commercial
cell culture medium, HyClone(TM) CDM4Avian, developed specifically
to address the challenges of media variability. The new medium
supports efficient and predictable virus production for
manufacturers utilizing EB66® cells, helping to increase production
reliability and improve end-product quality. Suitable for use
throughout the entire cell-growth process, CDM4Avian is
chemically-defined and free from animal-derived components, which
improves product consistency and simplifies the regulatory
processes for new products developed in EB66® cells.
Morgan Norris, General Manager for Upstream and Cell Culture, GE
Healthcare Life Sciences, said: "Working in close collaboration
with Valneva, and capturing their expertise in vaccine production,
has enabled us to successfully enhance productivity and create a
novel cell culture medium for a vaccine industry undergoing a
period of exciting change. The advent of cell-based production is
helping manufacturers meet the growing need for vaccines to address
global healthcare challenges."
Thomas Lingelbach, President and CEO, and Franck Grimaud, Deputy
CEO of Valneva, added: "This collaboration with GE has been very
successful and we are extremely pleased that our EB66® licensees
now have access to a medium that will greatly ease the development
of their new products. Coupled with the recent European Medicine
Agency's (EMA) decision to allow the production of live attenuated
vaccines in cell-lines like EB66®, this strongly supports the
choice of EB66® as a modern cell technology platform for vaccine
development and manufacturing."
Until now, only inactivated vaccines could be developed in EB66®
cells in Europe. The EMA recently decided to issue new guidelines
on vaccine production in immortal cell lines allowing Valneva's
partners to now utilize the EB66® cell line to develop and
manufacture live-attenuated vaccines (LAV), including Modified
Vaccinia Ankara (MVA)-based vaccines, measles and oncolytic
vaccines.
About HyClone(TM) CDM4Avian
CDM4Avian cell culture medium is a chemically defined (CD),
animal-derived component-free (ADCF) & serum free (SF) robust
formulation for virus production in bioprocess applications. It is
designed for scalable culture bioprocessing applications and can be
used for the development of viral vaccines in EB66® cells, for the
production of secreted viruses, such as measles, alphaviruses,
influenza A and B strains and for the manufacturing of
intracellular viruses, such as the modified vaccinia Ankara (MVA)
virus. It is a single-medium formulation used for both cell
propagation and viral production, available in liquid and dry
powder form. The medium allows direct adaptation of cells with
stable productivity and supports high peak cell density as well as
enhanced viral infectivity and productivity.
About the EB66 ® Cell Line
Valneva's EB66® cell line is a highly efficient platform for
vaccine production. It is derived from duck embryonic stem cells
and today represents a compelling alternative to the use of chicken
eggs for large scale manufacturing of human and veterinary
vaccines. EB66® is one of the most extensively studied and
characterized cell line available for use in human vaccine
development. More than 20 different families of viruses have been
shown to efficiently propagate in EB66® cells. To date, Valneva has
more than 35 license agreements with the world's largest
pharmaceutical companies for the use of its EB66® cell line
technology in both human and animal health vaccines. The first
human vaccine produced using the EB66® technology received
marketing approval in 2014 and the first veterinary vaccine in
2012.
About GE Healthcare
GE Healthcare provides transformational medical technologies and
services to meet the demand for increased access, enhanced quality
and more affordable healthcare around the world. GE (NYSE:
GE) works on things that matter - great people and technologies
taking on tough challenges. From medical imaging, software &
IT, patient monitoring and diagnostics to drug discovery,
biopharmaceutical manufacturing technologies and performance
improvement solutions, GE Healthcare helps medical professionals
deliver great healthcare to their patients. For more information
about GE Healthcare, visit our website
atwww.gehealthcare.com.
About Valneva SE
Valneva is a fully integrated vaccine company that specializes
in the development, manufacture and commercialization of innovative
vaccines with a mission to protect people from infectious diseases
through preventative medicine.
The Group seeks financial returns through focused R&D
investments in promising product candidates and growing financial
contributions from commercial products, striving towards financial
self-sustainability.
Valneva's portfolio includes two commercial vaccines for
travellers, IXIARO®/JESPECT® for the prevention of Japanese
Encephalitis and DUKORAL® indicated for the prevention of Cholera
and, in some countries, prevention of diarrhea caused by ETEC. The
Group has proprietary vaccines in development including candidates
against Pseudomonas aeruginosa, Clostridium difficile and Lyme
Borreliosis. A variety of partnerships with leading pharmaceutical
companies complement the Company's value proposition and include
vaccines being developed using Valneva's innovative and validated
technology platforms (EB66® vaccine production cell line, IC31®
adjuvant).
Valneva is listed on Euronext-Paris and the Vienna stock
exchange and has operations in France, Austria, Scotland, Canada
and Sweden with approximately 400 employees. More information is
available at www.valneva.com.
Contacts:
GE Healthcare
Saara Nordenström, GE Healthcare Life Sciences
M +46 7386 81286
saara.nordenstrom@ge.com
Valneva SE
Laetitia
Bachelot-Fontaine Teresa
Pinzolits
Head of Investor
Relations Corporate
Communications
& Corporate
Communications T
+43-1-206
20-1116
T
+02-28-07-14-19 M
+43-676-84 55 67 357
M +33 (0)6 4516
7099 Communications@valneva.com
Investors@valneva.com
2016_11_02 Valneva GE EB66 PR EN
http://hugin.info/143334/R/2053261/768485.pdf